Browse > Article

Broussonetia kazinoki Siebold stimulates immune response in ovalbumin-immunized mice  

Jung, Da-Young (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine)
Ha, Hye-Kyung (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine)
Lee, Ho-Young (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine)
Lee, Jin-Ah (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine)
Jeong, Seung-Il (Jeonju Biomaterials Institute)
Choi, Young-Jae (ChunYang Paper Co., Ltd.)
Shin, Hyeun-Kyoo (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine)
Publication Information
The Journal of Korean Medicine / v.32, no.3, 2011 , pp. 10-17 More about this Journal
Abstract
Objective: To evaluate the immune-stimulatory potential of extracts of Broussonetia kazinoki Siebold (BK) on specific cellular and humoral immune responses in ovalbumin (OVA)-immunized mice. Material and Methods: C57BL/6 mice were immunized intraperitoneally with OVA/alum ($100{\mu}g/200{\mu}g$) on days 1, 8, and 15. BK (100, 300 or 1000 mg/kg) was given to mice orally for 21 days (from day 1 to day 21). At day 22, OVA-, lipopolysaccharide (LPS)- and concanavalin A (Con A)-stimulated splenocyte proliferation and OVA-specific and total antibodies were measured in plasma. Further, the effects of BK on expression of cytokine mRNA in OVA-immunized mice splenocytes were evaluated by RT-PCR analysis. Results: BK significantly enhanced OVA-, LPS-, and Con A-induced splenocyte proliferation in OVA-immunized mice (p<0.01). BK also significantly enhanced total IgM and OVA-specific IgG1 levels in plasma compared with the OVA control group. Moreover, BK up-regulated significantly the expression of mRNA level of IL-2 and IFN-${\gamma}$ in splenocytes. Conclusions: BK has immune-stimulating activity in an OVA-immunized mouse model system, enhancing the Th1 immune response. BK showed no cytotoxicity in this system, suggesting that BK may be a safe and effective adjuvant in humans.
Keywords
Broussonetia kazinoki Siebold; OVA; splenocyte proliferation; antibody; adjuvant; immune response;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lee HJ, Park JH, Jang DI, Ryu JH. Antioxidant components from Broussonetia kazinoki. Yakhak Hoechi. 1997;41(4):439-443.
2 Roswitha F, Thomas M, Brigitte K, Paul GS. Stimulation nitric oxide synthesis by the aqueous Extract of Panax ginseg root in RAW 264.7 cells. Br J Pharmacol. 2001;134(8):1663-1670.   DOI   ScienceOn
3 Abbas AK, Lichtman AH. Basic immunology, functions and disorders of the immune system. 2nd ed. Philadelphia:Saunders. 2004.
4 Tizard IR. Veterinary immunology an introduction, 6th ed. Philadelphia:Saunders. 2000.
5 Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses the alternative approaches. Annu Rev Immunol. 1997;15: 297-322.   DOI   ScienceOn
6 Schirmbeck R, Melber K, Kuhrber A, Janowicz ZA. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted $CD8^{+}$ cytotoxic T lymphocyte responses in vivo. J Immunol. 1994;152(3):1110-1119.
7 Bae KH. Medical plants of Korea. Seoul:Kyohak publishing Co. 2000:65.
8 Ryu JH, Ahn H, Lee HJ. Inhibition of nitric oxide production on LPS-activated macrophages by kazinol B from Broussonetia kazinoki. Fitoterapia. 2003;74(4):350-354.   DOI   ScienceOn
9 Ko HH, Yen MH, Wu RR, Won SJ, Lin CN. Cytotoxic isoprenylated flavans of Broussonetia kazinoki. J Nat Prod. 1999;62(1):164-166.   DOI   ScienceOn
10 Zhang PC, Wang S, Wu Y, Chen RY, Yu DQ. Five new diprenylated flavonols from the leaves of Broussonetia kazinoki. J Nat Prod. 2001;64(9): 1206-1209.   DOI   ScienceOn
11 Tsukamoto D, Shibano M, Kusano G. Studies on the constituents of Broussonetia Species X. Six new alkaloids from Broussonetia kazinoki Sieb. Chem Pharm Bull. 2001a;49(11):1487-1491.   DOI   ScienceOn
12 Shibano M, Kitagawa S, Nakamura S, Akazawa N, Kusano G. Studies on the constituents of Broussonetia species. II Six new pyrrolidine alkaloids, broussonetine A, B, E, F and broussonetinine A and B, as inhibitors of glycosidases from Broussonetia kazinoki Sieb. Chem Pharm Bull. 1997;45(4):700-705.   DOI   ScienceOn
13 Shibano M, Nakamura S, Akazawa N, Kusano. Studies on the constituents of Broussonetia species. III. Two new pyrrolidine alkaloids, broussonetinines G and H, as inhibitors of glycosidase from Broussonetia kazinoki Sieb. Chem Pharm Bull. 1998;46(6):1048-1050.   DOI   ScienceOn
14 Shibano M, Tsukamoto D, Fujimoto R, Masui Y, Sugimoto H, Kusano G. Studies on the constituents of Broussonetia species. VII. Four new pyrrolidine alkaloids, broussonetines M, O, P, and Q, as inhibitors of glycosidase from Broussonetia kazinoki Sieb. Chem Pharm Bull. 2000;48(9):1281-1285.   DOI   ScienceOn
15 Tsukamoto D, Shibano M, Okamoto R, Kusano G. Studies on the constituents of Broussonetia species VIII. Four new pyrrolidine alkaloids, broussonetines R, S, T, and V and a new pyrroline alkaloid, roussonetine U, from Broussonetia kazinoki Sieb. Chem Pharm Bull. 2001b;49(4):492-496.   DOI   ScienceOn
16 Baek YS, Ryu YB, Curtis MJ, Ha TJ, Rengasamy R, Yang MS, et al. Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009;17(1):35-41.   DOI   ScienceOn
17 HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002;20(S3):S34-S39.   DOI
18 Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 1994;12(14):1275-1280.   DOI   ScienceOn
19 Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine. 1997;15(3):48-56.
20 Pascual DM, Morales RD, Gil ED, Munoz LM, Lopez JE, Casanueva, OLJ. Aduvants present regulatory challenges. Vaccine. 2006;24(S2): S88-S89.   DOI
21 Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce reactions man to vaccines containing tetanus and diphtheria toxoids. Vaccine. 1998;16(9-10):1016-1023.   DOI   ScienceOn